Andrew Benjamin Nixon
Professor in Medicine
Andrew Nixon, PhD, MBA (Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.
Current Appointments & Affiliations
- Professor in Medicine, Medicine, Medical Oncology, Medicine 2021
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1998
Contact Information
- 133 Jones, Research Drive, Durham, NC 27710
- Duke Box 2631, Durham, NC 27710
-
anixon@duke.edu
(919) 613-7883
- Background
-
Education, Training, & Certifications
- M.B.A., Duke University 2007
- Ph.D., Wake Forest University 1997
-
Previous Appointments & Affiliations
- Professor in Medicine, Medicine, Medical Oncology, Medicine 2019 - 2020
- Associate Professor in Medicine, Medicine, Medical Oncology, Medicine 2012 - 2019
- Assistant Professor in Medicine, Medicine, Medical Oncology, Medicine 2006 - 2012
- Assistant Research Professor of Medicine, Medicine, Medical Oncology, Medicine 2004 - 2006
- Expertise
-
Global Scholarship
-
Research
-
- Research
-
Selected Grants
- Drug Development for Dystonia awarded by Department of Defense 2023 - 2027
- Integrated analysis of a NLRP3-dependent adaptive resistance mechanism to pembrolizumab immunotherapy in advanced gastroesophageal cancer awarded by Merck Sharp & Dohme 2022 - 2026
- IL-6 in PDIGREE (AO31704) awarded by Alliance for Clinical Trials in Oncology Foundation 2020 - 2025
- A Randomized Phase 2 Trial to Evaluate Prebiotic Intervention in Allogeneic Hematopoietic Stem Cell Transplantation awarded by National Institutes of Health 2020 - 2025
- Clinical Biomarker Study of the Tumor NLRP3 Inflammasome and its Role in Anti-PD-1 Immunotherapy Resistance awarded by Conquer Cancer Foundation 2021 - 2024
- Anti-PD1 in combination with an inhibitor of PCSK9 to increase MHC class I molecule expression on tumor cells as immunotherapy for NSCLC awarded by Department of Defense 2021 - 2024
- Printed Electronic Biosensors for Point-of-Care Testing of Cardiovascular Biomarkers awarded by National Institutes of Health 2019 - 2024
- Immune signatures in metastatic colorectal cancer awarded by Genentech, Inc. 2017 - 2023
- A Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer awarded by Alliance Foundation Trials, LLC 2021 - 2023
- Identification and validation of plasma-based protein biomarkers for cediranib and olaparib in GY005, phase III awarded by NRG Oncology 2020 - 2023
- Brain Vasular Malformation Consortium: Predictors of clinical course awarded by The Regents of the University of California 2014 - 2023
- Mountaineer Biomarker Study: A Phase II, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HET2+ Metastatic Colorectal Cancer. awarded by Seattle Genetics, Inc 2020 - 2023
- Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer awarded by National Institutes of Health 2014 - 2023
- Single-cell cytokine profiling in metastatic colorectal cancer patients receiving immunotherapy awarded by Mario Family Foundation 2022
- Angiogenic biomarker discovery to direct bevacizumab therapy in cervical cancer - Blood-based Angiome Profiling: An ancillary analysis of GOG-0240 awarded by National Institutes of Health 2021 - 2022
- Home Transplant to Preserve the Microbiota and Decrease GVHD awarded by American Society of Hematology 2019 - 2022
- Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer awarded by Department of Defense 2018 - 2022
- Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer awarded by Department of Defense 2018 - 2022
- MSI in mCRC awarded by Promega 2020 - 2022
- Cell-Free DNA for Diagnosis of Malignancy, Genetic Mutations and Prognosis in Lung Cancer Related Pleural Effusions awarded by Department of Defense 2020 - 2022
- The role of Claudin-2 in metastatic colorectal cancer awarded by Seattle Genetics, Inc 2016 - 2022
- Blood-based Biomarker Profiling for TEW-7197 awarded by MedPacto, Inc 2017 - 2021
- Profiling the Adenosine Axis in Metastatic Colorectal Cancer awarded by MedImmune, Inc. 2018 - 2021
- AFT-42 Immune Cells awarded by Alliance Foundation Trials, LLC 2019 - 2021
- New strategies to improve drug development for carcinoid tumors awarded by University of California - San Francisco 2019 - 2021
- Pilot Study for Feasibility of Next Generation Sequencing for Detection of Lung Cancer ALK and ROS1 Mutation. awarded by HTG Molecular Diagnostics, Inc 2019 - 2021
- Angiome Profiling of GY012 awarded by NRG Oncology 2020 - 2021
- Identification and validation of plasma-based protein biomarkers for cediranib and olaparib awarded by Leidos Biomedical Research, Inc. 2019 - 2020
- Analysis of baseline blood samples from a clinical study evaluating TRC105 in metastatic renal cell carcinoma cancer patients awarded by Tracon Pharmaceuticals, Inc. 2017 - 2019
- Identification and validation of plasma-based protein biomarkers for cediranib and olaparib awarded by Leidos Biomedical Research, Inc. 2019
- Blood-based Biomarker Profiling for Regorafenib in Metastatic Colorectal Cancer awarded by University of North Carolina - Chapel Hill 2017 - 2019
- 3D Biology Signatures defined by Nanostring Max System awarded by North Carolina Biotechnology Center 2018 - 2019
- Dovitinib in Treating Patients with Recurrent or Progressive Glioblastoma awarded by Cleveland Clinic Foundation 2015 - 2018
- Anti-Tumor Effects of locally and Systemically Administered EZN-2279 monotherapy in a murine model of Colorectal Carcinoma awarded by Leadiant Biosciences, Inc. 2017 - 2018
- RAP-041 mediated modulation of intratumoral immune cell subpopulations in vivo and effect of combination treatment with anti-PD1 monoclonal antibody awarded by Acceleron Pharma 2016 - 2018
- Predictive value of the IL6 pathway to direct anti-angiogenic therapy in advanced ovarian cancer awarded by American Association of Obstetricians and Gynecologists Foundation 2017 - 2018
- Blood-based Biomarker Profiling for TEW-7197 awarded by MedPacto, Inc 2016 - 2018
- Preclinical and Human Correlative Studies of a Novel Bruton Tyronsine Kinase Inhibitor in Pancreatic Cancer awarded by Department of Defense 2016 - 2017
- Anti-endoglin mediated modulation of intratumoral Immune Cell Subpopulationg in vivo and effect of combination treatment with anti-PD1 monoclonal antibodies awarded by Tracon Pharmaceuticals, Inc. 2015 - 2017
- CTOT - Cell Free DNA awarded by Mount Sinai School of Medicine 2016 - 2017
- Biomarker Discovery to Direct Bevacizumab Therapy in Ovarian Cancer - Blood-based Angiome Profiling awarded by National Institutes of Health 2014 - 2017
- Janssen Research AGreement awarded by Janssen Research & Development, LLC 2014 - 2016
- The prevalence of MET gene amplification in metastatic colorectal cancer awarded by Amgen, Inc. 2014 - 2016
- Serum Biomarkers in Lymphoma awarded by Brigham and Women's Hospital 2014 - 2015
- (PQA5) 'Dose and Mechanisms of Exercise in Breast Cancer Prevention' awarded by National Institutes of Health 2013 - 2014
- Anti-VEGF in Tumors & Wounds: Efficacy vs Toxicity awarded by National Institutes of Health 2006 - 2012
- New Clinical Biomarker for Cancer--Wound Angiogenesis awarded by National Institutes of Health 2000 - 2006
- Regulation Of Cyclic Gmp Phosphodiesterase By Gz awarded by National Institutes of Health 1997 - 2001
-
External Relationships
- Alliance for Clinical Trials in Oncology
- Leap Therapeutics
- NRG Oncology
- National Cancer Intitute
- Promega Corporation
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Cheng, En, Qian Shi, Anthony F. Shields, Andrew B. Nixon, Ardaman P. Shergill, Chao Ma, Katherine A. Guthrie, et al. “Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer.” Jama Oncol 9, no. 3 (March 1, 2023): 404–13. https://doi.org/10.1001/jamaoncol.2022.6911.Full Text Link to Item
-
Mahmood, Kamran, Parvathi Jampani, Jeffrey M. Clarke, Steven Wolf, Xiaofei Wang, Momen M. Wahidi, Coral X. Giovacchini, et al. “High Yield of Pleural Cell-Free DNA for Diagnosis of Oncogenic Mutations in Lung Adenocarcinoma.” Chest, January 21, 2023. https://doi.org/10.1016/j.chest.2023.01.019.Full Text Link to Item
-
Harrington, Josephine, Andrew B. Nixon, Melissa A. Daubert, Eric Yow, James Januzzi, Mona Fiuzat, David J. Whellan, et al. “Circulating Angiokines Are Associated With Reverse Remodeling and Outcomes in Chronic Heart Failure.” J Card Fail, January 8, 2023. https://doi.org/10.1016/j.cardfail.2022.12.011.Full Text Link to Item
-
SenNet Consortium, Denise H. “NIH SenNet Consortium to map senescent cells throughout the human lifespan to understand physiological health.” Nat Aging 2, no. 12 (December 2022): 1090–1100. https://doi.org/10.1038/s43587-022-00326-5.Full Text Link to Item
-
Shah, Ankoor, Jan Storek, Rob Woolson, Ashley Pinckney, Lynnette Keyes-Elstein, Paul K. Wallace, Gregory D. Sempowski, et al. “Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy.” Rheumatology (Oxford) 61, no. 10 (October 6, 2022): 4155–62. https://doi.org/10.1093/rheumatology/keac015.Full Text Link to Item
-
Quintanilha, Julia C. F., Kelli Hammond, Yingmiao Liu, Federica Marmorino, Beatrice Borelli, Chiara Cremolini, Andrew B. Nixon, and Federico Innocenti. “Plasma levels of VEGF-A and VCAM-1 as predictors of drug-induced hypertension in patients treated with VEGF pathway inhibitors.” Br J Clin Pharmacol 88, no. 9 (September 2022): 4171–79. https://doi.org/10.1111/bcp.15356.Full Text Link to Item
-
Mehta, Rutika, Jessica Frakes, Jongphil Kim, Andrew Nixon, Yingmiao Liu, Lauren Howard, Maria E. Martinez Jimenez, et al. “Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma.” Oncologist 27, no. 8 (August 5, 2022): 621-e617. https://doi.org/10.1093/oncolo/oyac003.Full Text Link to Item
-
Shonibare, Zainab, Mehri Monavarian, Kathleen O’Connell, Diego Altomare, Abigail Shelton, Shubham Mehta, Renata Jaskula-Sztul, et al. “Reciprocal SOX2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer.” Cell Rep 40, no. 4 (July 26, 2022): 111066. https://doi.org/10.1016/j.celrep.2022.111066.Full Text Link to Item
-
Limkakeng, Alexander T., Laura-Leigh Rowlette, Ace Hatch, Andrew B. Nixon, Olga Ilkayeva, David Corcoran, Jennifer Modliszewski, Shannon Michelle Griffin, Geoffrey S. Ginsburg, and Deepak Voora. “A precision medicine approach to stress testing using metabolomics and microribonucleic acids.” Per Med 19, no. 4 (July 2022): 287–97. https://doi.org/10.2217/pme-2021-0021.Full Text Link to Item
-
Nixon, Andrew B., Alexander B. Sibley, Yingmiao Liu, Ace J. Hatch, Chen Jiang, Flora Mulkey, Mark D. Starr, et al. “Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).” Clin Cancer Res 28, no. 13 (July 1, 2022): 2779–88. https://doi.org/10.1158/1078-0432.CCR-21-2389.Full Text Link to Item
-
Nixon, Andrew B., Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev, Bin Luo, et al. “Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance).” Clin Cancer Res 28, no. 13 (July 1, 2022): 2771–78. https://doi.org/10.1158/1078-0432.CCR-21-2386.Full Text Link to Item
-
Horst, Ben, Shrikant Pradhan, Roohi Chaudhary, Eduardo Listik, Liz Quintero-Macias, Alex Seok Choi, Michael Southard, et al. “Hypoxia-induced inhibin promotes tumor growth and vascular permeability in ovarian cancers.” Commun Biol 5, no. 1 (June 2, 2022): 536. https://doi.org/10.1038/s42003-022-03495-6.Full Text Link to Item
-
Clarke, Jeffrey M., Lin Gu, Xiaofei F. Wang, Thomas E. Stinchcombe, Marvaretta M. Stevenson, Sundhar Ramalingam, Afreen Shariff, et al. “A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial.” Jto Clin Res Rep 3, no. 6 (June 2022): 100337. https://doi.org/10.1016/j.jtocrr.2022.100337.Full Text Link to Item
-
Lipsyc-Sharf, Marla, Sui Zhang, Fang-Shu Ou, Chao Ma, Nadine Jackson McCleary, Donna Niedzwiecki, I-Wen Chang, et al. “Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405.” J Natl Cancer Inst 114, no. 3 (March 8, 2022): 427–35. https://doi.org/10.1093/jnci/djab200.Full Text Link to Item
-
Jia, Jingquan, Lauren Howard, Yingmiao Liu, Mark D. Starr, John C. Brady, Donna Niedzwiecki, John H. Strickler, and Andrew B. Nixon. “Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.” Cancer Chemother Pharmacol 89, no. 3 (March 2022): 413–22. https://doi.org/10.1007/s00280-022-04404-8.Full Text Link to Item
-
Mettu, Niharika B., Fang-Shu Ou, Tyler J. Zemla, Thorvardur R. Halfdanarson, Heinz-Josef Lenz, Rimini A. Breakstone, Patrick M. Boland, et al. “Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.” Jama Netw Open 5, no. 2 (February 1, 2022): e2149040. https://doi.org/10.1001/jamanetworkopen.2021.49040.Full Text Link to Item
-
Quintanilha, Julia C. F., Yingmiao Liu, Amy S. Etheridge, Akram Yazdani, Hedy L. Kindler, William Kevin Kelly, Andrew B. Nixon, and Federico Innocenti. “Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance).” Angiogenesis 25, no. 1 (February 2022): 47–55. https://doi.org/10.1007/s10456-021-09799-1.Full Text Link to Item
-
Siamakpour-Reihani, Sharareh, Felicia Cao, Jing Lyu, Yi Ren, Andrew B. Nixon, Jichun Xie, Amy T. Bush, et al. “Evaluating immune response and metabolic related biomarkers pre-allogenic hematopoietic stem cell transplant in acute myeloid leukemia.” Plos One 17, no. 6 (2022): e0268963. https://doi.org/10.1371/journal.pone.0268963.Full Text Link to Item
-
Taniguchi, Hiroya, Takayuki Yoshino, Kensei Yamaguchi, Kentaro Yamazaki, Andrew B. Nixon, Josep Tabernero, Eric Van Cutsem, et al. “Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study.” Curr Med Res Opin 37, no. 10 (October 2021): 1769–78. https://doi.org/10.1080/03007995.2021.1940908.Full Text Link to Item
-
Wetzel-Strong, Sarah E., Shantel Weinsheimer, Jeffrey Nelson, Ludmila Pawlikowska, Dewi Clark, Mark D. Starr, Yingmiao Liu, et al. “Pilot investigation of circulating angiogenic and inflammatory biomarkers associated with vascular malformations.” Orphanet J Rare Dis 16, no. 1 (September 3, 2021): 372. https://doi.org/10.1186/s13023-021-02009-7.Full Text Link to Item
-
Choueiri, Toni K., Yousef Zakharia, Sumanta Pal, Judit Kocsis, Russell Pachynski, Alexandr Poprach, Andrew B. Nixon, et al. “Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR).” Oncologist 26, no. 7 (July 2021): 560-e1103. https://doi.org/10.1002/onco.13777.Full Text Link to Item
-
Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.” Clin Cancer Res 27, no. 12 (June 15, 2021): 3317–28. https://doi.org/10.1158/1078-0432.CCR-20-4504.Full Text Link to Item
-
Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma.” Clin Cancer Res 27, no. 12 (June 15, 2021): 3503. https://doi.org/10.1158/1078-0432.CCR-21-1636.Full Text Link to Item
-
Dorry, Michael, Kevin Davidson, Rajesh Dash, Rachel Jug, Jeffrey M. Clarke, Andrew B. Nixon, and Kamran Mahmood. “Pleural effusions associated with squamous cell lung carcinoma have a low diagnostic yield and a poor prognosis.” Transl Lung Cancer Res 10, no. 6 (June 2021): 2500–2508. https://doi.org/10.21037/tlcr-21-123.Full Text Link to Item
-
Strickler, John H., Christel N. Rushing, Hope E. Uronis, Michael A. Morse, Donna Niedzwiecki, Gerard C. Blobe, Ashley N. Moyer, et al. “Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.” Oncologist 26, no. 6 (June 2021): 465-e917. https://doi.org/10.1002/onco.13678.Full Text Link to Item
-
Buechel, Megan E., Danielle Enserro, Robert A. Burger, Mark F. Brady, Katrina Wade, Angeles Alvarez Secord, Andrew B. Nixon, et al. “Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).” Gynecol Oncol 161, no. 2 (May 2021): 382–88. https://doi.org/10.1016/j.ygyno.2021.02.032.Full Text Link to Item
-
Guercio, Brendan J., Sui Zhang, Fang-Shu Ou, Alan P. Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, et al. “IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405.” Jnci Cancer Spectr 5, no. 1 (February 2021). https://doi.org/10.1093/jncics/pkaa074.Full Text Link to Item
-
Ramalingam, Sendhilnathan, Sharareh Siamakpour-Reihani, Lauren Bohannan, Yi Ren, Alexander Sibley, Jeff Sheng, Li Ma, et al. “A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.” Plos One 16, no. 6 (January 2021): e0252995. https://doi.org/10.1371/journal.pone.0252995.Full Text
-
Liu, Yingmiao, Madelon Paauwe, Andrew B. Nixon, and Lukas J. A. C. Hawinkels. “Endoglin Targeting: Lessons Learned and Questions That Remain.” Int J Mol Sci 22, no. 1 (December 25, 2020). https://doi.org/10.3390/ijms22010147.Full Text Link to Item
-
Mackintosh, Christopher, Chen Yuan, Fang-Shu Ou, Sui Zhang, Donna Niedzwiecki, I-Wen Chang, Bert H. O’Neil, et al. “Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer.” Jama Oncol 6, no. 11 (November 1, 2020): 1713–21. https://doi.org/10.1001/jamaoncol.2020.3938.Full Text Link to Item
-
Liu, Yingmiao, Jing Lyu, Kirsten Bell Burdett, Alexander B. Sibley, Ace J. Hatch, Mark D. Starr, John C. Brady, et al. “Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib.” Mol Cancer Ther 19, no. 10 (October 2020): 2146–54. https://doi.org/10.1158/1535-7163.MCT-20-0249.Full Text Link to Item
-
Lampert, Erika J., Alexandra Zimmer, Michelle Padget, Ashley Cimino-Mathews, Jayakumar R. Nair, Yingmiao Liu, Elizabeth M. Swisher, et al. “Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.” Clin Cancer Res 26, no. 16 (August 15, 2020): 4268–79. https://doi.org/10.1158/1078-0432.CCR-20-0056.Full Text Link to Item
-
Kim, Richard D., Hanna K. Sanoff, Andrew S. Poklepovic, Heloisa Soares, Jongphil Kim, Jing Lyu, Yingmiao Liu, Andrew B. Nixon, and Dae Won Kim. “A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.” Cancer 126, no. 15 (August 1, 2020): 3464–70. https://doi.org/10.1002/cncr.32964.Full Text Link to Item
-
Schoonderwoerd, Mark J. A., Maaike F. M. Koops, Ricardo A. Angela, Bryan Koolmoes, Melpomeni Toitou, Madelon Paauwe, Marieke C. Barnhoorn, et al. “Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy.” Clin Cancer Res 26, no. 14 (July 15, 2020): 3831–42. https://doi.org/10.1158/1078-0432.CCR-19-2889.Full Text Link to Item
-
Sung, Anthony D., Shekeab Jauhari, Sharareh Siamakpour-Reihani, Arati V. Rao, Janet Staats, Cliburn Chan, Everett Meyer, et al. “Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.” Am J Hematol 95, no. 6 (June 2020): 662–71. https://doi.org/10.1002/ajh.25781.Full Text Link to Item
-
Theivanthiran, Balamayoora, Kathy S. Evans, Nicholas C. DeVito, Michael Plebanek, Michael Sturdivant, Luke P. Wachsmuth, April Ks Salama, et al. “A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.” J Clin Invest 130, no. 5 (May 1, 2020): 2570–86. https://doi.org/10.1172/JCI133055.Full Text Link to Item
-
Alvarez Secord, Angeles, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu, Mark D. Starr, et al. “Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.” Clin Cancer Res 26, no. 6 (March 15, 2020): 1288–96. https://doi.org/10.1158/1078-0432.CCR-19-0226.Full Text Link to Item
-
Siamakpour-Reihani, Sharareh, Lauren Patterson Cobb, Chen Jiang, Dadong Zhang, Rebecca A. Previs, Kouros Owzar, Andrew B. Nixon, and Angeles Alvarez Secord. “Differential expression of immune related genes in high-grade ovarian serous carcinoma.” Gynecol Oncol 156, no. 3 (March 2020): 662–68. https://doi.org/10.1016/j.ygyno.2019.12.019.Full Text Link to Item
-
Limkakeng, Alexander T., Laura-Leigh Rowlette, Ace Hatch, Andrew B. Nixon, Olga Ilkayeva, David L. Corcoran, Jennifer L. Modliszewski, et al. “A Precision Medicine Approach to Stress Testing Using Metabolomics and Microribonucleic Acids,” February 6, 2020. https://doi.org/10.1101/2020.02.06.936757.Full Text
-
Reed, Christopher Robert, Christopher Cameron McCoy, Uttara Nag, Andrew B. Nixon, James Otto, Jeffrey Harold Lawson, Andrew J. Lodge, Joseph W. Turek, and Elisabeth Tomlinson Tracy. “Proteomic Analysis of Infants Undergoing Cardiopulmonary Bypass Using Contemporary Ontological Tools.” J Surg Res 246 (February 2020): 83–92. https://doi.org/10.1016/j.jss.2019.08.019.Full Text Link to Item
-
Nixon, Andrew B., Kurt A. Schalper, Ira Jacobs, Shobha Potluri, I-Ming Wang, and Catherine Fleener. “Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?” J Immunother Cancer 7, no. 1 (November 27, 2019): 325. https://doi.org/10.1186/s40425-019-0799-2.Full Text Link to Item
-
George, Daniel J., Susan Halabi, Patrick Healy, Ian Barak, Carolyn Winters, Monika Anand, Rhonda Wilder, et al. “Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.” Prostate 79, no. 15 (November 2019): 1752–61. https://doi.org/10.1002/pros.23899.Full Text Link to Item
-
Strickler, John H., Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S David Hsu, et al. “A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.” Bmc Cancer 19, no. 1 (November 1, 2019): 1032. https://doi.org/10.1186/s12885-019-6234-8.Full Text Link to Item
-
Clarke, Jeffrey Melson, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, S Yousuf Zafar, Michael Morse, Evan Dropkin, et al. “A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).” Cancer Chemother Pharmacol 84, no. 4 (October 2019): 909–17. https://doi.org/10.1007/s00280-019-03916-0.Full Text Link to Item
-
Sharma, Mayur, Cathy Schilero, David M. Peereboom, Brian P. Hobbs, Paul Elson, Glen H. J. Stevens, Keith McCrae, Andrew B. Nixon, and Manmeet S. Ahluwalia. “Phase II study of Dovitinib in recurrent glioblastoma.” J Neurooncol 144, no. 2 (September 2019): 359–68. https://doi.org/10.1007/s11060-019-03236-6.Full Text Link to Item
-
Innocenti, Federico, Chen Jiang, Alexander B. Sibley, Stefanie Denning, Amy S. Etheridge, Dorothy Watson, Donna Niedzwiecki, et al. “An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).” Pharmacogenet Genomics 29, no. 6 (August 2019): 123–31. https://doi.org/10.1097/FPC.0000000000000375.Full Text Link to Item
-
Gbenedio, Oghenekevwe M., Caroline Bonnans, Delphine Grun, Chih-Yang Wang, Ace J. Hatch, Michelle R. Mahoney, David Barras, et al. “RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.” Jci Insight 5, no. 15 (June 25, 2019). https://doi.org/10.1172/jci.insight.127552.Full Text Link to Item
-
Lin, Jiaxing, Alexander Sibley, Ivo Shterev, Andrew Nixon, Federico Innocenti, Cliburn Chan, and Kouros Owzar. “fastJT: An R package for robust and efficient feature selection for machine learning and genome-wide association studies.” Bmc Bioinformatics 20, no. 1 (June 13, 2019): 333. https://doi.org/10.1186/s12859-019-2869-3.Full Text Link to Item
-
Kelly, Francine L., Kaitlyn E. Weinberg, Andrew E. Nagler, Andrew B. Nixon, Mark D. Star, Jamie L. Todd, David M. Brass, and Scott M. Palmer. “EGFR-Dependent IL8 Production by Airway Epithelial Cells After Exposure to the Food Flavoring Chemical 2,3-Butanedione.” Toxicol Sci 169, no. 2 (June 1, 2019): 534–42. https://doi.org/10.1093/toxsci/kfz066.Full Text Link to Item
-
Secord, Angeles Alvarez, Michael McCollum, Brittany A. Davidson, Gloria Broadwater, Robert Squatrito, Laura J. Havrilesky, Anne C. Gabel, et al. “Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.” Gynecol Oncol 153, no. 3 (June 2019): 555–61. https://doi.org/10.1016/j.ygyno.2019.03.246.Full Text Link to Item
-
Hsi, Eric D., Hongli Li, Andrew B. Nixon, Heiko Schöder, Nancy L. Bartlett, Michael LeBlanc, Sonali Smith, et al. “Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.” Blood 133, no. 16 (April 18, 2019): 1762–65. https://doi.org/10.1182/blood-2018-08-870915.Full Text Link to Item
-
Choueiri, Toni K., M Dror Michaelson, Edwin M. Posadas, Guru P. Sonpavde, David F. McDermott, Andrew B. Nixon, Yingmiao Liu, et al. “An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.” Oncologist 24, no. 2 (February 2019): 202–10. https://doi.org/10.1634/theoncologist.2018-0299.Full Text Link to Item
-
Corradetti, Michael N., Jordan A. Torok, Ace J. Hatch, Eric P. Xanthopoulos, Kyle Lafata, Corbin Jacobs, Christel Rushing, et al. “Dynamic Changes in Circulating Tumor DNA During Chemoradiation for Locally Advanced Lung Cancer.” Adv Radiat Oncol 4, no. 4 (2019): 748–52. https://doi.org/10.1016/j.adro.2019.05.004.Full Text Link to Item
-
Innocenti, Federico, Chen Jiang, Alexander B. Sibley, Amy S. Etheridge, Ace J. Hatch, Stefanie Denning, Donna Niedzwiecki, et al. “Genetic variation determines VEGF-A plasma levels in cancer patients.” Sci Rep 8, no. 1 (November 5, 2018): 16332. https://doi.org/10.1038/s41598-018-34506-4.Full Text Link to Item
-
Liu, Yingmiao, Mark D. Starr, John C. Brady, Christel Rushing, Herbert Pang, Bonne Adams, Delia Alvarez, Charles P. Theuer, Herbert I. Hurwitz, and Andrew B. Nixon. “Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105.” Mol Cancer Ther 17, no. 10 (October 2018): 2248–56. https://doi.org/10.1158/1535-7163.MCT-17-0916.Full Text Link to Item
-
Melosky, Barbara, David A. Reardon, Andrew B. Nixon, Janakiraman Subramanian, Angel H. Bair, and Ira Jacobs. “Bevacizumab biosimilars: scientific justification for extrapolation of indications.” Future Oncol 14, no. 24 (October 2018): 2507–20. https://doi.org/10.2217/fon-2018-0051.Full Text Link to Item
-
Secord, Angeles Alvarez, Rebecca A. Previs, and Andrew B. Nixon. “Cabozantinib in ovarian clear cell cancers: UnMET expectations.” Gynecol Oncol 150, no. 1 (July 2018): 1–2. https://doi.org/10.1016/j.ygyno.2018.06.006.Full Text Link to Item
-
Vlahovic, Gordana, Kellen L. Meadows, Ace J. Hatch, Jingquan Jia, Andrew B. Nixon, Hope E. Uronis, Michael A. Morse, et al. “A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.” Oncologist 23, no. 7 (July 2018): 782–90. https://doi.org/10.1634/theoncologist.2016-0377.Full Text Link to Item
-
Seligmann, Jenny F., Ace J. Hatch, Susan D. Richman, Faye Elliott, Bart Jacobs, Sarah Brown, Herbert Hurwitz, et al. “Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.” Jama Oncol 4, no. 4 (April 1, 2018): 564–68. https://doi.org/10.1001/jamaoncol.2017.3168.Full Text Link to Item
-
Ronald, James, Andrew B. Nixon, Daniele Marin, Rajan T. Gupta, Gemini Janas, Willa Chen, Paul V. Suhocki, et al. “Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma.” Radiology 285, no. 1 (October 2017): 311–18. https://doi.org/10.1148/radiol.2017162555.Full Text Link to Item
-
Thompson, Eric M., Stephen T. Keir, Talaignair Venkatraman, Christopher Lascola, Kristen W. Yeom, Andrew B. Nixon, Yingmiao Liu, et al. “The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival.” Neuro Oncol 19, no. 9 (September 1, 2017): 1217–27. https://doi.org/10.1093/neuonc/nox033.Full Text Link to Item
-
Waters, Joshua C., Andrew Nixon, Morgan Dwyer, Justin C. Biffinger, and Kwangwon Lee. “Developing elite Neurospora crassa strains for cellulosic ethanol production using fungal breeding.” J Ind Microbiol Biotechnol 44, no. 8 (August 2017): 1137–44. https://doi.org/10.1007/s10295-017-1941-0.Full Text Link to Item
-
Hesler, Rachel A., Jennifer J. Huang, Mark D. Starr, Victoria M. Treboschi, Alyssa G. Bernanke, Andrew B. Nixon, Shannon J. McCall, Rebekah R. White, and Gerard C. Blobe. “TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.” Carcinogenesis 37, no. 11 (November 1, 2016): 1041–51. https://doi.org/10.1093/carcin/bgw093.Full Text Link to Item
-
Zhang, Tian, Jason Zhu, Daniel J. George, and Andrew B. Nixon. “Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.” Urol Oncol 34, no. 11 (November 2016): 510–18. https://doi.org/10.1016/j.urolonc.2016.06.020.Full Text Link to Item
-
Hatch, Ace J., Alexander B. Sibley, Mark D. Starr, J Chris Brady, Chen Jiang, Jingquan Jia, Daniel L. Bowers, et al. “Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).” Cancer Med 5, no. 9 (September 2016): 2249–60. https://doi.org/10.1002/cam4.806.Full Text Link to Item
-
Keefe, S. M., J. Hoffman-Censits, R. B. Cohen, R. Mamtani, D. Heitjan, S. Eliasof, A. Nixon, et al. “Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.” Ann Oncol 27, no. 8 (August 2016): 1579–85. https://doi.org/10.1093/annonc/mdw188.Full Text Link to Item
-
Hackett, Sara L., Benjamin Davis, Andrew Nixon, and Ruth Wyatt. “Constancy checks of well-type ionization chambers with external-beam radiation units.” J Appl Clin Med Phys 16, no. 6 (November 8, 2015): 508–14. https://doi.org/10.1120/jacmp.v16i6.5608.Full Text Link to Item
-
Kim, Hyung L., Susan Halabi, Ping Li, Greg Mayhew, Jeff Simko, Andrew B. Nixon, Eric J. Small, et al. “A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance).” Ebiomedicine 2, no. 11 (November 2015): 1814–20. https://doi.org/10.1016/j.ebiom.2015.09.012.Full Text Link to Item
-
Jia, Jingquan, Andrew E. Dellinger, Eric S. Weiss, Anuradha Bulusu, Christel Rushing, Haiyan Li, Leigh A. Howard, et al. “Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing.” Clin Cancer Res 21, no. 15 (August 1, 2015): 3442–52. https://doi.org/10.1158/1078-0432.CCR-14-2819.Full Text Link to Item
-
Liu, Yingmiao, Mark D. Starr, John C. Brady, Christel Rushing, Anuradha Bulusu, Herbert Pang, Wanda Honeycutt, et al. “Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus.” Mol Cancer Ther 14, no. 4 (April 2015): 1048–56. https://doi.org/10.1158/1535-7163.MCT-14-0923-T.Full Text Link to Item
-
Cushman, Stephanie M., Chen Jiang, Ace J. Hatch, Ivo Shterev, Alexander B. Sibley, Donna Niedzwiecki, Alan P. Venook, Kouros Owzar, Herbert I. Hurwitz, and Andrew B. Nixon. “Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).” Clin Cancer Res 21, no. 5 (March 1, 2015): 1078–86. https://doi.org/10.1158/1078-0432.CCR-14-2313.Full Text Link to Item
-
Rushing, Christel, Anuradha Bulusu, Herbert I. Hurwitz, Andrew B. Nixon, and Herbert Pang. “A leave-one-out cross-validation SAS macro for the identification of markers associated with survival.” Comput Biol Med 57 (February 2015): 123–29. https://doi.org/10.1016/j.compbiomed.2014.11.015.Full Text Link to Item
-
Uronis, Hope E., Jingquan Jia, Johanna C. Bendell, Leigh Howard, Neal A. Ready, Paula H. Lee, Mark D. Starr, et al. “A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors.” Cancer Chemother Pharmacol 75, no. 2 (February 2015): 343–52. https://doi.org/10.1007/s00280-014-2647-x.Full Text Link to Item
-
Hatch, Ace J., Jeffrey M. Clarke, Andrew B. Nixon, and Herbert I. Hurwitz. “Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress.” Cancer J 21, no. 4 (2015): 322–26. https://doi.org/10.1097/PPO.0000000000000129.Full Text Link to Item
-
Secord, Angeles Alvarez, Andrew B. Nixon, and Herbert I. Hurwitz. “The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.” Gynecol Oncol 135, no. 2 (November 2014): 349–58. https://doi.org/10.1016/j.ygyno.2014.08.033.Full Text Link to Item
-
Liu, Yingmiao, Hongyu Tian, Gerard C. Blobe, Charles P. Theuer, Herbert I. Hurwitz, and Andrew B. Nixon. “Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.” Invest New Drugs 32, no. 5 (October 2014): 851–59. https://doi.org/10.1007/s10637-014-0129-y.Full Text Link to Item
-
Elderbroom, Jennifer L., Jennifer J. Huang, Catherine E. Gatza, Jian Chen, Tam How, Mark Starr, Andrew B. Nixon, and Gerard C. Blobe. “Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion.” Mol Biol Cell 25, no. 16 (August 15, 2014): 2320–32. https://doi.org/10.1091/mbc.E13-09-0524.Full Text Link to Item
-
Bitting, Rhonda L., Patrick Healy, Patricia A. Creel, James Turnbull, Karla Morris, Sarah Yenser Wood, Herbert I. Hurwitz, et al. “A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.” Clin Genitourin Cancer 12, no. 4 (August 2014): 241–50. https://doi.org/10.1016/j.clgc.2013.11.020.Full Text Link to Item
-
Meyer, Alison E., Catherine E. Gatza, Tam How, Mark Starr, Andrew B. Nixon, and Gerard C. Blobe. “Role of TGF-β receptor III localization in polarity and breast cancer progression.” Mol Biol Cell 25, no. 15 (August 1, 2014): 2291–2304. https://doi.org/10.1091/mbc.E14-03-0825.Full Text Link to Item
-
Rangwala, Fatima, Johanna C. Bendell, Mark F. Kozloff, Christy C. Arrowood, Andrew Dellinger, Jennifer Meadows, Sandra Tourt-Uhlig, et al. “Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.” Invest New Drugs 32, no. 4 (August 2014): 700–709. https://doi.org/10.1007/s10637-014-0089-2.Full Text Link to Item
-
Dellinger, A. E., A. B. Nixon, and H. Pang. “Integrative pathway analysis using Graph-Based learning with applications to TCGA colon and ovarian data.” Cancer Informatics 13, no. SUPPL.4 (July 28, 2014). https://doi.org/10.4137/CIN.S13634.Full Text
-
Kumar, S., C. C. Pan, J. C. Bloodworth, A. B. Nixon, C. Theuer, D. G. Hoyt, and N. Y. Lee. “Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling.” Oncogene 33, no. 30 (July 24, 2014): 3970–79. https://doi.org/10.1038/onc.2013.386.Full Text Link to Item
-
Knelson, Erik H., Angela L. Gaviglio, Jasmine C. Nee, Mark D. Starr, Andrew B. Nixon, Stephen G. Marcus, and Gerard C. Blobe. “Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth.” J Clin Invest 124, no. 7 (July 2014): 3016–31. https://doi.org/10.1172/JCI74270.Full Text Link to Item
-
Gatza, Catherine E., Jennifer L. Elderbroom, Sun Young Oh, Mark D. Starr, Andrew B. Nixon, and Gerard C. Blobe. “The balance of cell surface and soluble type III TGF-β receptor regulates BMP signaling in normal and cancerous mammary epithelial cells.” Neoplasia 16, no. 6 (June 2014): 489–500. https://doi.org/10.1016/j.neo.2014.05.008.Full Text Link to Item
-
Liu, Yingmiao, Mark D. Starr, John C. Brady, Andrew Dellinger, Herbert Pang, Bonne Adams, Charles P. Theuer, Nam Y. Lee, Herbert I. Hurwitz, and Andrew B. Nixon. “Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.” Cancer Med 3, no. 3 (June 2014): 580–91. https://doi.org/10.1002/cam4.207.Full Text Link to Item
-
Strickler, John H., Shannon McCall, Andrew B. Nixon, John C. Brady, Herbert Pang, Christel Rushing, Allen Cohn, et al. “Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.” Invest New Drugs 32, no. 2 (April 2014): 330–39. https://doi.org/10.1007/s10637-013-0042-9.Full Text Link to Item
-
Secord, Angeles Alvarez, Deanna Teoh, Jingquan Jia, Andrew B. Nixon, Lisa Grace, David J. Adams, and Susan K. Murphy. “Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.” Int J Gynecol Cancer 24, no. 2 (February 2014): 218–25. https://doi.org/10.1097/IGC.0000000000000056.Full Text Link to Item
-
Dellinger, Andrew E., Andrew B. Nixon, and Herbert Pang. “Integrative Pathway Analysis Using Graph-Based Learning with Applications to TCGA Colon and Ovarian Data.” Cancer Inform 13, no. Suppl 4 (2014): 1–9. https://doi.org/10.4137/CIN.S13634.Full Text Link to Item
-
Kumar, S., C. C. Pan, J. C. Bloodworth, A. B. Nixon, C. Theuer, D. G. Hoyt, and N. Y. Lee. “Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling.” Oncogene 33, no. 30 (2014): 3970–79. https://doi.org/10.1038/onc.2013.386.Full Text
-
Lopez-Acevedo, Micael, Lisa Grace, Deanna Teoh, Regina Whitaker, David J. Adams, Jingquan Jia, Andrew B. Nixon, and Angeles Alvarez Secord. “Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines.” Gynecol Oncol Res Pract 1 (2014): 2. https://doi.org/10.1186/2053-6844-1-2.Full Text Open Access Copy Link to Item
-
Nixon, Andrew B., Herbert Pang, Mark D. Starr, Paula N. Friedman, Monica M. Bertagnolli, Hedy L. Kindler, Richard M. Goldberg, Alan P. Venook, Herbert I. Hurwitz, and Herbert I. Alliance for Clinical Trials In Oncology. “Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).” Clin Cancer Res 19, no. 24 (December 15, 2013): 6957–66. https://doi.org/10.1158/1078-0432.CCR-13-0926.Full Text Link to Item
-
Hanks, Brent A., Alisha Holtzhausen, Katherine S. Evans, Rebekah Jamieson, Petra Gimpel, Olivia M. Campbell, Melissa Hector-Greene, et al. “Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.” J Clin Invest 123, no. 9 (September 2013): 3925–40. https://doi.org/10.1172/JCI65745.Full Text Open Access Copy Link to Item
-
Uronis, Hope E., Stephanie M. Cushman, Johanna C. Bendell, Gerard C. Blobe, Michael A. Morse, Andrew B. Nixon, Andrew Dellinger, et al. “A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.” Cancer Med 2, no. 3 (June 2013): 316–24. https://doi.org/10.1002/cam4.65.Full Text Open Access Copy Link to Item
-
Liu, Yingmiao, Mark D. Starr, Anuradha Bulusu, Herbert Pang, Nan Soon Wong, Wanda Honeycutt, Anthony Amara, Herbert I. Hurwitz, and Andrew B. Nixon. “Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.” Cancer Med 2, no. 2 (April 2013): 234–42. https://doi.org/10.1002/cam4.71.Full Text Link to Item
-
Jia, Jingquan, Alex Starodub, Ian Cushman, Yingmiao Liu, Deborah J. Marshall, Herbert I. Hurwitz, and Andrew B. Nixon. “Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.” Anticancer Drugs 24, no. 3 (March 2013): 237–50. https://doi.org/10.1097/CAD.0b013e32835d29fd.Full Text Link to Item
-
Uronis, Hope E., Johanna C. Bendell, Ivy Altomare, Gerard C. Blobe, S David Hsu, Michael A. Morse, Herbert Pang, et al. “A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.” Oncologist 18, no. 3 (2013): 271–72. https://doi.org/10.1634/theoncologist.2012-0404.Full Text Link to Item
-
Strickler, John H., Alexander N. Starodub, Jingquan Jia, Kellen L. Meadows, Andrew B. Nixon, Andrew Dellinger, Michael A. Morse, et al. “Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.” Cancer Chemother Pharmacol 70, no. 2 (August 2012): 251–58. https://doi.org/10.1007/s00280-012-1911-1.Full Text Link to Item
-
Liu, Y., M. Starr, H. Pang, J. Marcello, B. R. Leigh, C. P. Theuer, H. Hurwitz, and A. B. Nixon. “Modulation of angiogenic biomarkers in patients treated on a phase I study of TRC105 (anti-CD105 antibody) monotherapy for advanced solid tumors.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 10565.Link to Item
-
Nixon, A. B., H. Pang, M. Starr, D. Hollis, P. N. Friedman, M. M. Bertagnolli, H. L. Kindler, R. M. Goldberg, A. P. Venook, and H. Hurwitz. “Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 10508.Link to Item
-
Wong, Nan Soon, Nishan H. Fernando, Andrew B. Nixon, Stephanie Cushman, Mebea Aklilu, Johanna C. Bendell, Michael A. Morse, et al. “A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.” Anticancer Res 31, no. 1 (January 2011): 255–61.Link to Item
-
Tailor, Tina D., Gabi Hanna, Pavel S. Yarmolenko, Matthew R. Dreher, Allison S. Betof, Andrew B. Nixon, Ivan Spasojevic, and Mark W. Dewhirst. “Effect of pazopanib on tumor microenvironment and liposome delivery.” Mol Cancer Ther 9, no. 6 (June 2010): 1798–1808. https://doi.org/10.1158/1535-7163.MCT-09-0856.Full Text Link to Item
-
Dugan, Elizabeth, Roxanne Truax, Kellen L. Meadows, Andrew B. Nixon, William P. Petros, Justin Favaro, Nishan H. Fernando, Michael A. Morse, Gerard C. Blobe, and Herbert I. Hurwitz. “A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.” Anticancer Res 30, no. 4 (April 2010): 1251–56.Link to Item
-
Facemire, Carie S., Andrew B. Nixon, Robert Griffiths, Herbert Hurwitz, and Thomas M. Coffman. “Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression.” Hypertension 54, no. 3 (September 2009): 652–58. https://doi.org/10.1161/HYPERTENSIONAHA.109.129973.Full Text Link to Item
-
Starodub, A., J. Jia, S. Cushman, D. Marshall, H. I. Hurwitz, and A. B. Nixon. “Dual inhibition of αV integrins and Src kinase activity in colon cancer cells.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): e14609.Link to Item
-
Bullock, K. E., H. I. Hurwitz, H. E. Uronis, M. A. Morse, G. C. Blobe, S. D. Hsu, S. Y. Zafar, A. B. Nixon, L. A. Howard, and J. C. Bendell. “Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC).” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 4080.Link to Item
-
Howard, L. A., K. E. Bullock, J. C. Bendell, H. E. Uronis, G. Vlahovic, G. C. Blobe, R. F. Riedel, A. B. Nixon, J. P. Gockerman, and H. I. Hurwitz. “Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 3551.Link to Item
-
Osada, Takuya, Gabriel Chong, Robert Tansik, Timothy Hong, Neil Spector, Rakesh Kumar, Herbert I. Hurwitz, et al. “The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.” Cancer Immunol Immunother 57, no. 8 (August 2008): 1115–24. https://doi.org/10.1007/s00262-007-0441-x.Full Text Link to Item
-
Kimple, Michelle E., Andrew B. Nixon, Patrick Kelly, Candice L. Bailey, Kenneth H. Young, Timothy A. Fields, and Patrick J. Casey. “A role for G(z) in pancreatic islet beta-cell biology.” J Biol Chem 280, no. 36 (September 9, 2005): 31708–13. https://doi.org/10.1074/jbc.M506700200.Full Text Link to Item
-
Nixon, Andrew B., and Patrick J. Casey. “Analysis of the regulation of microtubule dynamics by interaction of RGSZ1 (RGS20) with the neuronal stathmin, SCG10.” Methods Enzymol 390 (2004): 53–64. https://doi.org/10.1016/S0076-6879(04)90004-3.Full Text Link to Item
-
Baker, Paul R. S., John S. Owen, Andrew B. Nixon, Leslie N. Thomas, Rhonda Wooten, Larry W. Daniel, Joseph T. O’Flaherty, and Robert L. Wykle. “Regulation of platelet-activating factor synthesis in human neutrophils by MAP kinases.” Biochim Biophys Acta 1592, no. 2 (October 21, 2002): 175–84. https://doi.org/10.1016/s0167-4889(02)00314-2.Full Text Link to Item
-
Hubbert, Charlotte, Amaris Guardiola, Rong Shao, Yoshiharu Kawaguchi, Akihiro Ito, Andrew Nixon, Minoru Yoshida, Xiao-Fan Wang, and Tso-Pang Yao. “HDAC6 is a microtubule-associated deacetylase.” Nature 417, no. 6887 (May 23, 2002): 455–58. https://doi.org/10.1038/417455a.Full Text Link to Item
-
Nixon, Andrew B., Gabriele Grenningloh, and Patrick J. Casey. “The interaction of RGSZ1 with SCG10 attenuates the ability of SCG10 to promote microtubule disassembly.” J Biol Chem 277, no. 20 (May 17, 2002): 18127–33. https://doi.org/10.1074/jbc.M201065200.Full Text Link to Item
-
Burgon, P. G., W. L. Lee, A. B. Nixon, E. G. Peralta, and P. J. Casey. “Phosphorylation and nuclear translocation of a regulator of G protein signaling (RGS10).” J Biol Chem 276, no. 35 (August 31, 2001): 32828–34. https://doi.org/10.1074/jbc.M100960200.Full Text Link to Item
-
Burgon, P. G., W. L. Lee, A. B. Nixon, P. J. Casey, and E. G. Peralta. “Phosphorylation and nuclear translocation of a regulator of G-protein signaling (RGS10).” Faseb Journal 14, no. 8 (May 11, 2000): A1483–A1483.Link to Item
-
Nixon, A. B., J. T. O’Flaherty, J. K. Salyer, and R. L. Wykle. “Acetyl-CoA:1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase is directly activated by p38 kinase.” J Biol Chem 274, no. 9 (February 26, 1999): 5469–73. https://doi.org/10.1074/jbc.274.9.5469.Full Text Link to Item
-
Seeds, M. C., A. B. Nixon, R. L. Wykle, and D. A. Bass. “Differential activation of human neutrophil cytosolic phospholipase A2 and secretory phospholipase A2 during priming by 1,2-diacyl- and 1-O-alkyl-2-acylglycerols.” Biochim Biophys Acta 1394, no. 2–3 (November 2, 1998): 224–34. https://doi.org/10.1016/s0005-2760(98)00111-8.Full Text Link to Item
-
Nixon, A. B., M. C. Seeds, D. A. Bass, P. K. Smitherman, J. T. O’Flaherty, L. W. Daniel, and R. L. Wykle. “Comparison of alkylacylglycerol vs. diacylglycerol as activators of mitogen-activated protein kinase and cytosolic phospholipase A2 in human neutrophil priming.” Biochim Biophys Acta 1347, no. 2–3 (August 16, 1997): 219–30. https://doi.org/10.1016/s0005-2760(97)00077-5.Full Text Link to Item
-
Nixon, A. B. “Comparison of alkylacylglycerol (eag) and diacylglycerol (aag) as activators of map kinase(s) and cytosolic pla2 in human neutrophil priming.” Faseb Journal 10, no. 6 (December 1, 1996).
-
Nixon, A. B., M. C. Seeds, P. K. Smilherman, P. A. Bass, and R. L. Wvkle. “Comparison of alkylacylglycerol (EAG) and diacylglycerol (AAG) as activators of map kjnase(s) and cytosolic PLA2 in human neutrophil priming.” Faseb Journal 10, no. 6 (December 1, 1996).
-
O’Flaherty, J. T., M. Kuroki, A. B. Nixon, J. Wijkander, E. Yee, S. L. Lee, P. K. Smitherman, R. L. Wykle, and L. W. Daniel. “5-Oxo-eicosanoids and hematopoietic cytokines cooperate in stimulating neutrophil function and the mitogen-activated protein kinase pathway.” J Biol Chem 271, no. 30 (July 26, 1996): 17821–28. https://doi.org/10.1074/jbc.271.30.17821.Full Text Link to Item
-
O’Flaherty, J. T., M. Kuroki, A. B. Nixon, J. Wijkander, E. Yee, S. L. Lee, P. K. Smitherman, R. L. Wykle, and L. W. Daniel. “5-Oxo-eicosatetraenoate is a broadly active, eosinophil-selective stimulus for human granulocytes.” J Immunol 157, no. 1 (July 1, 1996): 336–42.Link to Item
-
Nixon, A. B., D. G. Greene, and R. L. Wykle. “Comparison of acceptor and donor substrates in the CoA-independent transacylase reaction in human neutrophils.” Biochim Biophys Acta 1300, no. 3 (May 20, 1996): 187–96. https://doi.org/10.1016/0005-2760(96)00011-2.Full Text Link to Item
-
Seeds, M. C., A. B. Nixon, R. L. Wykle, and D. A. Bass. “Differential activation of human neutrophil cytosolic and secretory phospholipase a2 's during priming by 1,2-DIACYL- And 1O-ALKYL-2-Acylglycerols.” Journal of Investigative Medicine 44, no. 3 (January 1, 1996).
-
Wykle, R. L., J. Wijkander, A. B. Nixon, L. W. Daniel, and J. T. O’Flaherty. “Activation of 85 kDa PLA2 by eicosanoids in human neutrophils and eosinophils.” Adv Exp Med Biol 416 (1996): 327–31. https://doi.org/10.1007/978-1-4899-0179-8_52.Full Text Link to Item
-
Wijkander, J., J. T. O’Flaherty, A. B. Nixon, and R. L. Wykle. “5-Lipoxygenase products modulate the activity of the 85-kDa phospholipase A2 in human neutrophils.” J Biol Chem 270, no. 44 (November 3, 1995): 26543–49. https://doi.org/10.1074/jbc.270.44.26543.Full Text Link to Item
-
Winkler, J. D., A. N. Fonteh, C. M. Sung, J. D. Heravi, A. B. Nixon, M. Chabot-Fletcher, D. Griswold, L. A. Marshall, and F. H. Chilton. “Effects of CoA-independent transacylase inhibitors on the production of lipid inflammatory mediators.” J Pharmacol Exp Ther 274, no. 3 (September 1995): 1338–47.Link to Item
-
Strum, J. C., A. B. Nixon, L. W. Daniel, and R. L. Wykle. “Evaluation of phospholipase C and D activity in stimulated human neutrophils using a phosphono analog of choline phosphoglyceride.” Biochim Biophys Acta 1169, no. 1 (July 21, 1993): 25–29. https://doi.org/10.1016/0005-2760(93)90077-m.Full Text Link to Item
-
Schmitt, J. D., A. B. Nixon, A. Emilsson, L. W. Daniel, and R. L. Wykle. “A facile synthesis of 1-O-alkyl-2-(R)-hydroxypropane-3-phosphonocholine (lyso-phosphono-platelet activating factor).” Chem Phys Lipids 62, no. 3 (October 1992): 263–68. https://doi.org/10.1016/0009-3084(92)90063-u.Full Text Link to Item
-
-
Other Articles
-
Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 3 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478720.Full Text
-
Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 1 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478726.v1.Full Text
-
Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 4a from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478714.v1.Full Text
-
Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 1 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478726.Full Text
-
Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Tables and Figures from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478711.Full Text
-
Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 4a from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478714.Full Text
-
Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 4B from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478717.v1.Full Text
-
Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 2 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478723.Full Text
-
Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 3 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478720.v1.Full Text
-
Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 4B from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478717.Full Text
-
Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Figure 2 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478723.v1.Full Text
-
Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Data from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.c.6530027.v1.Full Text
-
Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Data from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.c.6530027.Full Text
-
Armstrong, Andrew J., Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, et al. “Supplementary Tables and Figures from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma,” March 31, 2023. https://doi.org/10.1158/1078-0432.22478711.v1.Full Text
-
Lampert, Erika J., Alexandra Zimmer, Michelle Padget, Ashley Cimino-Mathews, Jayakumar R. Nair, Yingmiao Liu, Elizabeth M. Swisher, et al. “Supplementary Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.22479107.v1.Full Text
-
Lampert, Erika J., Alexandra Zimmer, Michelle Padget, Ashley Cimino-Mathews, Jayakumar R. Nair, Yingmiao Liu, Elizabeth M. Swisher, et al. “Supplementary Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.22479107.Full Text
-
Lampert, Erika J., Alexandra Zimmer, Michelle Padget, Ashley Cimino-Mathews, Jayakumar R. Nair, Yingmiao Liu, Elizabeth M. Swisher, et al. “Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.c.6530135.Full Text
-
Lampert, Erika J., Alexandra Zimmer, Michelle Padget, Ashley Cimino-Mathews, Jayakumar R. Nair, Yingmiao Liu, Elizabeth M. Swisher, et al. “Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.c.6530135.v1.Full Text
-
Nixon, Andrew B., Alexander B. Sibley, Yingmiao Liu, Ace J. Hatch, Chen Jiang, Flora Mulkey, Mark D. Starr, et al. “Supplementary Table from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance),” March 31, 2023. https://doi.org/10.1158/1078-0432.22483455.Full Text
-
Nixon, Andrew B., Alexander B. Sibley, Yingmiao Liu, Ace J. Hatch, Chen Jiang, Flora Mulkey, Mark D. Starr, et al. “Data from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance),” March 31, 2023. https://doi.org/10.1158/1078-0432.c.6531153.v1.Full Text
-
Nixon, Andrew B., Alexander B. Sibley, Yingmiao Liu, Ace J. Hatch, Chen Jiang, Flora Mulkey, Mark D. Starr, et al. “Supplementary Figure from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance),” March 31, 2023. https://doi.org/10.1158/1078-0432.22483458.v1.Full Text
-
Nixon, Andrew B., Alexander B. Sibley, Yingmiao Liu, Ace J. Hatch, Chen Jiang, Flora Mulkey, Mark D. Starr, et al. “Supplementary Table from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance),” March 31, 2023. https://doi.org/10.1158/1078-0432.22483455.v1.Full Text
-
Nixon, Andrew B., Alexander B. Sibley, Yingmiao Liu, Ace J. Hatch, Chen Jiang, Flora Mulkey, Mark D. Starr, et al. “Data from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance),” March 31, 2023. https://doi.org/10.1158/1078-0432.c.6531153.Full Text
-
Nixon, Andrew B., Alexander B. Sibley, Yingmiao Liu, Ace J. Hatch, Chen Jiang, Flora Mulkey, Mark D. Starr, et al. “Supplementary Figure from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance),” March 31, 2023. https://doi.org/10.1158/1078-0432.22483458.Full Text
-
Nixon, Andrew B., Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev, Bin Luo, et al. “Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance),” March 31, 2023. https://doi.org/10.1158/1078-0432.c.6531354.v1.Full Text
-
Nixon, Andrew B., Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev, Bin Luo, et al. “Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance),” March 31, 2023. https://doi.org/10.1158/1078-0432.c.6531354.Full Text
-
Nixon, Andrew B., Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev, Bin Luo, et al. “Supplementary Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance),” March 31, 2023. https://doi.org/10.1158/1078-0432.22484208.Full Text
-
Nixon, Andrew B., Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev, Bin Luo, et al. “Supplementary Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance),” March 31, 2023. https://doi.org/10.1158/1078-0432.22484208.v1.Full Text
-
-
Conference Papers
-
Park, Haeseong, Aravind Sanjeevaiah, Peter Joel Hosein, Rutika Mehta, Ramon Jin, Patrick Grierson, Rama Suresh, et al. “Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Final analysis of a phase II trial.” In Journal of Clinical Oncology, 40:284–284. American Society of Clinical Oncology (ASCO), 2022. https://doi.org/10.1200/jco.2022.40.4_suppl.284.Full Text
-
Cheng, En, Shi Qian, Anthony F. Shields, Elizabeth M Cespedes Feliciano, Andrew B. Nixon, Ardaman P. Shergill, Katherine A. Guthrie, et al. “Associations of inflammatory biomarkers with survival among patients with stage III colon cancer (CALGB/SWOG 80702 [Alliance]).” In Cancer Research, Vol. 82, 2022.Link to Item
-
Hostetler, H., M. L. Neely, F. L. Kelly, A. B. Nixon, J. Londry, B. Silva, N. Gulbahce, R. N. Woodward, S. M. Palmer, and J. L. Todd. “Bronchoalveolar Lavage Fluid (BALF) as a Compartment for DonorDerived Cell-Free DNA (dd-cfDNA) Assessment in Lung Recipients.” In Journal of Heart and Lung Transplantation, 41:S155–S155, 2022.Link to Item
-
Hostetler, H., M. L. Neely, F. L. Kelly, A. B. Nixon, J. Londry, R. N. Woodward, S. M. Palmer, and J. L. Todd. “Performance of Donor-Derived Cell-Free DNA (dd-cfDNA) for Discriminating Acute Lung Allograft Injury in a Multicenter Cohort.” In Journal of Heart and Lung Transplantation, 41:S74–S74, 2022.Link to Item
-
Kohn, Christine G., Fang-Shu Ou, Chao Ma, Nicholas B. Larson, Tyler J. Zemla, Chen Yuan, Donna Niedzwiecki, et al. “Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance).” In Journal of Clinical Oncology, Vol. 40, 2022.Link to Item
-
Shonibare, Zainab M., Mehri Monavarian, Kathleen O’Connell, Diego Altamore, Abigail Shelton, Shubham Mehta, Renata Jaskula-Sztul, et al. “Reciprocal Sox2 regulation by SMAD1 and SMAD3 is critical for anoikis resistance and metastasis in ovarian cancer.” In Cancer Research, Vol. 82, 2022.Link to Item
-
DiNardo, Katherine, Chao Ma, Fang-Shu Ou, Chen Yuan, Brendan John Guercio, Vicente Morales-Oyarvide, Erin Van Blarigan, et al. “Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405.” In Journal of Clinical Oncology, 39:3568–3568. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.3568.Full Text
-
Halabi, Susan, Qian Yang, Mark D. Starr, John C. Brady, Andrew J. Armstrong, Daniel J. George, William Kevin Kelly, Himisha Beltran, Michael J. Morris, and Andrew B. Nixon. “Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance).” In Journal of Clinical Oncology, 39:154–154. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.6_suppl.154.Full Text
-
Dercle, Laurent, Susan Michelle Geyer, Andrew B. Nixon, Federico Innocenti, Qian Shi, Sawyer B. Jacobson, Lyndon Luk, et al. “Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative science from CALGB 80802 (Alliance).” In Journal of Clinical Oncology, 39:343–343. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.3_suppl.343.Full Text
-
El Dika, Imane H., Susan Michelle Geyer, Andrew B. Nixon, Federico Innocenti, Qian Shi, Sawyer B. Jacobson, Amin Yaqubie, et al. “Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).” In Journal of Clinical Oncology, 39:325–325. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.3_suppl.325.Full Text
-
Geyer, Susan Michelle, Michelle R. Mahoney, Timothy R. Asmis, Nathan Hall, Sanja Karovic, Michael V. Knopp, Priya Kumthekar, et al. “Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.” In Journal of Clinical Oncology, 39:361–361. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.3_suppl.361.Full Text
-
Gaillard, S., G. Broadwater, W. S. Andrews, M. D. Starr, R. A. Previs, L. J. Havrilesky, B. A. Davidson, et al. “Pembrolizumab window study: Illuminating the immunologic landscape in gynecologic cancers.” In Gynecologic Oncology, 159:41–41. Elsevier BV, 2020. https://doi.org/10.1016/j.ygyno.2020.06.087.Full Text
-
Zhang, Tian, Yuan Wu, Anika Agarwal, Mark D. Starr, Marco Reyes-Martinez, Monika Anand, Daniella Runyambo, et al. “Longitudinal multiplex cytokine analysis for patients (pts) with metastatic renalcell carcinoma (mRCC) treated with ipilimumab/nivolumab (I plus N).” In Journal of Clinical Oncology, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.Link to Item
-
Hafez, Navid, Hatem Hussein Soliman, Siqing Fu, Karen A. Gelmon, Albiruni Ryan Abdul Razak, Pamela N. Munster, Ulka N. Vaishampayan, et al. “Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.” In Journal of Clinical Oncology, Vol. 38, 2020.Link to Item
-
Jia, Jingquan, Donna Niedzwiecki, Christy Arrowood, Nancy Garett-Mead, Rebecca Nagy, Richard B. Lanman, John Wright, Andrew B. Nixon, and John H. Strickler. “A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with MET amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA.” In Journal of Clinical Oncology, Vol. 38, 2020.Link to Item
-
Kim, Joseph W., Navid Hafez, Hatem Hussein Soliman, Siqing Fu, Shumei Kato, Primo Lara, Ulka N. Vaishampayan, et al. “Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.” In Journal of Clinical Oncology, Vol. 38, 2020.Link to Item
-
Kozono, David E., Elad Sharon, Jennifer Le-Rademacher, Erin Twohy, Tyler J. Zemla, Yujia Wen, Mark Watson, et al. “Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events.” In Journal of Clinical Oncology, Vol. 38, 2020.Link to Item
-
Arrillaga-Romany, Isabel, Solmaz Sahebjam, David Picconi, Jian Campian, Pierre Giglio, Jan Drappatz, Robert Aiken, et al. “A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA.” In Neuro Oncology, 21:27–27. OXFORD UNIV PRESS INC, 2019.Link to Item
-
Mettu, N. B., E. Twohy, F. -. S. Ou, T. R. Halfdanarson, H. J. Lenz, R. Breakstone, P. M. Boland, et al. “BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study.” In Annals of Oncology, Vol. 30. OXFORD UNIV PRESS, 2019.Link to Item
-
Das, R., F. Ou, C. Washburn, F. Innocenti, A. Nixon, H. Lenz, C. Blanke, et al. “Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identify a heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC).” In Ann Oncol, 30 Suppl 4:iv116, 2019. https://doi.org/10.1093/annonc/mdz156.019.Full Text Link to Item
-
Mettu, Niharika B., Donna Niedzwiecki, Christel Rushing, Andrew B. Nixon, Jingquan Jia, Sherri Haley, Wanda Honeycutt, Herbert Hurwitz, Johanna C. Bendell, and Hope Uronis. “A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.” In Cancer Chemother Pharmacol, 83:1025–35, 2019. https://doi.org/10.1007/s00280-019-03805-6.Full Text Link to Item
-
Bergsland, Emily K., Michelle R. Mahoney, Timothy R. Asmis, Nathan Hall, Priya Kumthekar, Michael L. Maitland, Donna Niedzwiecki, et al. “Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).” In Journal of Clinical Oncology, 37:4005–4005. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.4005.Full Text
-
Guercio, Brendan John, Alan P. Venook, Sui Zhang, Fang-Shu Ou, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, et al. “Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance).” In Journal of Clinical Oncology, 37:3035–3035. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.3035.Full Text
-
Isaacs, James, Andrew B. Nixon, Emily Bolch, Katie Quinn, Kimberly Banks, Brent Allen Hanks, and John H. Strickler. “Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers.” In Journal of Clinical Oncology, 37:3552–3552. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.3552.Full Text
-
Kim, Dae Won, Hanna Kelly Sanoff, Andrew Stewart Poklepovic, Fatima Tariq, Andrew B. Nixon, Yingmiao Liu, and Richard D. Kim. “Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC).” In Journal of Clinical Oncology, 37:4083–4083. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.4083.Full Text
-
Park, Haeseong, Nikolaos Trikalinos, Aravind Sanjeevaiah, Katrina Pedersen, Nusayba Ali Bagegni, Andrew B. Nixon, Jesse Huffman, et al. “Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma.” In Journal of Clinical Oncology, 37:TPS4150–TPS4150. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.tps4150.Full Text
-
Sinicrope, Frank A., Fang-Shu Ou, Tyler Zemla, Andrew B. Nixon, Kabir Mody, Alexandra Levasseur, Amylou C. Dueck, et al. “Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502).” In Journal of Clinical Oncology, 37:e15169–e15169. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e15169.Full Text
-
Hatch, Ace Joseph, Fang-Shu Ou, Tyler Zemla, Mark D. Starr, John C. Brady, Yingmiao Liu, Federico Innocenti, et al. “On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance).” In Journal of Clinical Oncology, 37:588–588. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.4_suppl.588.Full Text
-
Liu, Yingmiao, Kirsten Burdett, Mark D. Starr, J Chris Brady, Ace Joseph Hatch, Anastasia Ivanova, Dominic T. Moore, et al. “Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029.” In Journal of Clinical Oncology, 37:587–587. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.4_suppl.587.Full Text
-
Das, R. K., L. Furchtgott, F. -. S. Ou, D. Swanson, B. Hayete, B. Harms, D. Cunha, et al. “Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC).” In Ann Oncol, 29 Suppl 8:viii152, 2018. https://doi.org/10.1093/annonc/mdy281.006.Full Text Link to Item
-
Innocenti, F., C. Jiang, A. B. Sibley, S. Denning, A. S. Etheridge, D. Watson, D. Niedzwiecki, et al. “A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients.” In Ann Oncol, 29 Suppl 8:viii661–62, 2018. https://doi.org/10.1093/annonc/mdy303.038.Full Text Link to Item
-
Secord, A Alvarez, M. McCollum, B. Davidson, G. Broadwater, R. Squatrito, L. Havrilesky, A. Gabel, A. Nixon, and L. Duska. “PHASE II TRIAL OF NINTEDANIB IN PATIENTS WITH BEVACIZUMAB-RESISTANT RECURRENT EPITHELIAL OVARIAN, TUBAL, AND PERITONEAL CANCER.” In International Journal of Gynecological Cancer, 28:457–457. BMJ PUBLISHING GROUP, 2018.Link to Item
-
Buechel, Megan, Danielle Enserro, Robert Allen Burger, Mark F. Brady, Katrina Wade, Angeles Alvarez Secord, Andrew B. Nixon, et al. “Correlation of imaging and plasma-based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC): A GOG 218 ancillary data analysis.” In Journal of Clinical Oncology, 36:5507–5507. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5507.Full Text
-
Das, Rahul K., Leon Furchtgott, Jeffrey A. Meyerhardt, Andrew B. Nixon, Federico Innocenti, Daniel Cunha, Kelly Rich, et al. “Causal modeling of CALGB 80405 (Alliance) to identify network drivers of metastatic colorectal cancer (CRC).” In Journal of Clinical Oncology, 36:3570–3570. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.3570.Full Text
-
Jia, Jingquan, Donna Niedzwiecki, Hope Elizabeth Uronis, Michael Morse, Yousuf Zafar, Shiaowen David Hsu, Emily Bolch, et al. “A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.” In Journal of Clinical Oncology, 36:3555–3555. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.3555.Full Text
-
Kim, Richard D., Andrew Stewart Poklepovic, Andrew B. Nixon, Dae Won Kim, Heloisa P. Soares, Jongphil Kim, Jun Min Zhou, Fatima Tariq, Natalie Burgess, and Hanna Kelly Sanoff. “Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.” In Journal of Clinical Oncology, 36:4082–4082. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.4082.Full Text
-
Corradetti, M. N., A. J. Hatch, J. Torok, E. P. Xanthopoulos, C. N. Rushing, J. Calaway, G. Jones, A. B. Nixon, and C. R. Kelsey. “Dynamic Changes in Cell-Free DNA During Chemoradiation for Non–small Cell Lung Cancer.” In International Journal of Radiation Oncology*Biology*Physics, 99:S114–15. Elsevier BV, 2017. https://doi.org/10.1016/j.ijrobp.2017.06.270.Full Text
-
Furchtgott, Leon, David Swanson, Boris Hayete, Iya Khalil, Diane Wuest, Kelly Rich, Andrew B. Nixon, et al. “Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary (1o) tumor side.” In Journal of Clinical Oncology, 35:3528–3528. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.3528.Full Text
-
George, Daniel J., Susan Halabi, Mark D. Starr, Herbert Hurwitz, John C. Brady, Ian Barak, Michael J. Morris, et al. “Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance).” In Journal of Clinical Oncology, 35:4522–4522. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.4522.Full Text
-
Liu, Yingmiao, Zhenhua Yuan, Dadong Zhang, Mark D. Starr, John C. Brady, Manoj A. Jivani, Bonne J. Adams, et al. “Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.” In Journal of Clinical Oncology, 35:11546–11546. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.11546.Full Text
-
Sinicrope, Frank A., Fang-Shu Ou, Qian Shi, Andrew B. Nixon, Kabir Mody, Alexandra Levasseur, Amylou C. Dueck, et al. “Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502).” In Journal of Clinical Oncology, 35:TPS3630–TPS3630. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.tps3630.Full Text
-
Thompson, Eric M., Stephen Keir, Talaignair Venkatraman, Christopher Lascola, Kristen Yeom, Andrew Nixon, Yingmiao Liu, et al. “Angiogenesis plays a critical role in Group 3 medulloblastoma pathogenesis.” In Journal of Neurosurgery, 126:A1436–A1436. AMER ASSOC NEUROLOGICAL SURGEONS, 2017.Link to Item
-
Innocenti, Federico, Chen Jiang, Alexander Sibley, Amy Etheridge, Yoichi Furukawa, Michiaki Kubo, Hedy L. Kindler, et al. “Abstract 3388: Genetic prediction of VEGF-A plasma levels in cancer patients.” In Cancer Research, 76:3388–3388. American Association for Cancer Research (AACR), 2016. https://doi.org/10.1158/1538-7445.am2016-3388.Full Text
-
Nixon, Andrew B., Alexander Sibley, Ace Joseph Hatch, Yingmiao Liu, Chen Jiang, Flora Mulkey, Mark D. Starr, et al. “Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).” In Journal of Clinical Oncology, 34:3597–3597. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.3597.Full Text
-
Secord, Angeles Alvarez, David Tritchler, Yingmiao Liu, Mark D. Starr, John C. Brady, Heather A. Lankes, Herbert Hurwitz, et al. “Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.” In Journal of Clinical Oncology, 34:5521–5521. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.5521.Full Text
-
Ahluwalia, Manmeet Singh, Nikolaos Papadantonakis, Vyshak Alva Venur, Cathy Schilero, David M. Peereboom, Glen Stevens, Steven Rosenfeld, et al. “Phase II trial of dovitinib in recurrent glioblastoma.” In Journal of Clinical Oncology, 33:2050–2050. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2050.Full Text
-
Keefe, Stephen Michael, Jean H. Hoffman-Censits, Ronac Mamtani, Mary Walicki, Janelle Robinson, Abigail Smith, Orvar Gunnarsson, et al. “HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev).” In Journal of Clinical Oncology, 33:4543–4543. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.4543.Full Text
-
Seligmann, Jenny F., Faye Elliott, Bart Jacobs, Ace Joseph Hatch, Alexander Sibley, Susan Richman, Chen Jiang, et al. “HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC).” In Journal of Clinical Oncology, 33:3583–3583. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.3583.Full Text
-
Kim, Hyung, Susan Halabi, Ping Li, Greg Mayhew, Jeff Simko, Andrew Nixon, Eric Small, et al. “MP44-01 A PROGNOSTIC MODEL FOR OVERALL SURVIVAL IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CARCINOMA: RESULTS FROM CALGB 90206 (ALLIANCE).” In Journal of Urology, Vol. 193. Ovid Technologies (Wolters Kluwer Health), 2015. https://doi.org/10.1016/j.juro.2015.02.1543.Full Text
-
Clarke, Jeffrey Melson, Herbert Pang, Mark D. Starr, Ace Joseph Hatch, Hedy Lee Kindler, Eileen Mary O’Reilly, Federico Innocenti, Alan P. Venook, Herbert Hurwitz, and Andrew B. Nixon. “Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance).” In Journal of Clinical Oncology, 33:306–306. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.3_suppl.306.Full Text
-
Keefe, Stephen M., Jean Hoffman-Censits, Roger B. Cohen, Scott Eliasof, Edward G. Garmey, Orvar Gunnarsson, Meliessa Hennessy, et al. “HIF inhibition in metastatic renal cell carcinoma (RCC): FINAL results from a phase 1-2a clinical trial evaluating the nanoparticle-drug conjugate, CRLX101, in combination with bevacizumab.” In Bju International, 116:10–11, 2015.Link to Item
-
Knelson, Erik H., Angela L. Gaviglio, Jasmine C. Nee, Mark D. Starr, Andrew B. Nixon, Stephen G. Marcus, and Gerard C. Blobe. “Abstract 2674: Stroma biology identifies heparins as differentiating agents in neuroblastoma.” In Cancer Research, 74:2674–2674. American Association for Cancer Research (AACR), 2014. https://doi.org/10.1158/1538-7445.am2014-2674.Full Text
-
Hatch, Ace Joseph, Herbert Pang, Mark D. Starr, John C. Brady, Jingquan Jia, Chen Jiang, Alexander Sibley, et al. “Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).” In Journal of Clinical Oncology, 32:11022–11022. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.11022.Full Text
-
Kluger, Harriet M., Susan Halabi, Nicole C. Solomon, Lucia Jilaveanu, Christopher Zito, Joshua Sznol, Andrew B. Nixon, Brian I. Rini, Eric Jay Small, and Daniel J. George. “Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.” In Journal of Clinical Oncology, 32:4532–4532. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.4532.Full Text
-
Liu, Yingmiao, Jeffrey Melson Clarke, Mark D. Starr, John C. Brady, Herbert Pang, Christel Rushing, Delia Alvarez, et al. “Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial.” In Journal of Clinical Oncology, 32:11020–11020. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.11020.Full Text
-
Hatch, Ace J., Herbert Pang, Mark D. Starr, John C. Brady, Jingquan Jia, Donna Niedzwiecki, Alan Paul Venook, Stephanie M. Cushman, Herbert Hurwitz, and Andrew B. Nixon. “Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).” In Journal of Clinical Oncology, 32:448–448. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.3_suppl.448.Full Text
-
Heymach, John, Hai T. Tran, Andrew B. Nixon, Herbert Hurwitz, Jeffrey R. Infante, Robert C. Gagnon, Klaudia Steplewski, Ngocdiep T. Le, and Yuan Liu. “Circulating cytokines and angiogenic factors (CAF) as markers of clinical response in the study of trametinib (T) plus gemcitabine (G) versus placebo (P) plus gemcitabine for patients (pts) with untreated metastatic adenocarcinoma of the pancreas (MEK113487).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Hurwitz, Herbert, Stephanie Cushman, Chen Jiang, Ivo Shterev, Michelle R. Mahoney, Donna Niedzwiecki, Robert J. Mayer, Alan Paul Venook, Kouros Owzar, and Andrew B. Nixon. “Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Nixon, Andrew B., Susan Halabi, Ivo Shterev, Mark Starr, John C. Brady, Janice P. Dutcher, Judith O. Hopkins, et al. “Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Strickler, John H., Shannon McCall, Andrew B. Nixon, Herbert Pang, Christel Rushing, Christy Arrowood, Sherri Haley, Kellen Meadows, and Herbert Hurwitz. “Correlation of Src activation with response to dasatinib, capecitabine, oxaliplatin, and bevacizumab in advanced solid tumors.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.Link to Item
-
Knelson, Erik H., Angela L. Gaviglio, Alok K. Tewari, Michael B. Armstrong, Andrew B. Nixon, Mark D. Starr, Karthikeyan Mythreye, and Gerard C. Blobe. “Abstract 5041: The type III TGF-beta receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.” In Cancer Research, 73:5041–5041. American Association for Cancer Research (AACR), 2013. https://doi.org/10.1158/1538-7445.am2013-5041.Full Text
-
Jia, Jingquan, Haiyan Li, Andrew Dellinger, Herbert Pang, Karen Bullock Russell, Herbert Hurwitz, and Andrew B. Nixon. “Modulation of pharmacodynamic (PD) biomarkers in dermal biopsies from patients treated on a phase I study of bevacizumab (Bev) in combination with everolimus (Ev) and erlotinib (Erl) for advanced solid tumors.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Liu, Yingmiao, Mark Starr, John C. Brady, Herbert Pang, Andrew Dellinger, Bryan R. Leigh, Charles P. Theuer, Herbert Hurwitz, and Andrew B. Nixon. “Modulation of angiogenic biomarkers in patients receiving high-dose TRC105.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Acevedo, M Lopez, D. Teoh, D. Adams, A. Nixon, J. Jingquan, L. Grace, R. Whitaker, and A. Alvarez-Secord. “Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in leiomyosarcoma cell lines.” In Gynecologic Oncology, 125:S137–S137. Elsevier BV, 2012. https://doi.org/10.1016/j.ygyno.2011.12.334.Full Text
-
Hanna, G., G. Palmer, W. Park, J. Herbert, Y. Cao, T. Schroeder, G. Vlahovic, A. Nixon, and M. Dewhirst. “Variation in Microenvironmental Effects and Drug Delivery between Different Classes of Antiangiogenic Drugs.” In International Journal of Radiation Oncology*Biology*Physics, 78:S164–65. Elsevier BV, 2010. https://doi.org/10.1016/j.ijrobp.2010.07.405.Full Text
-
Bullock, K. E., H. I. Hurwitz, H. E. Uronis, M. A. Morse, G. C. Blobe, S. D. Hsu, S. Y. Zafar, A. B. Nixon, L. A. Howard, and J. C. Bendell. “Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Howard, L. A., K. E. Bullock, J. C. Bendell, H. E. Uronis, G. Vlahovic, G. C. Blobe, R. F. Riedel, A. B. Nixon, J. P. Gockerman, and H. I. Hurwitz. “Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Starodub, A., J. Jia, S. Cushman, D. Marshall, H. I. Hurwitz, and A. B. Nixon. “Dual inhibition of alpha(V) integrins and Src kinase activity in colon cancer cells.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Facemire, Carie, Campbell Frey, Andrew Nixon, Herbert Hurwitz, and Thomas Coffman. “Inhibition of vascular endothelial growth factor receptor 2 in mice causes hypertension and suppresses the renin-angiotensin system.” In Hypertension, 52:E106–E106. LIPPINCOTT WILLIAMS & WILKINS, 2008.Link to Item
-
Uronis, H. E., J. Bendell, G. Blobe, M. Morse, D. Geier, A. Nixon, L. Howard, D. Evans, H. Li, and H. Hurwitz. “A phase I study of bevacizumab (BV) plus ABT-510 in patients with advanced solid tumors.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.Link to Item
-
Baker, P. R. S., J. S. Owen, A. B. Nixon, L. Thomas, J. T. O’Flaherty, and R. L. Wykle. “Regulation of platelet-activating factor synthesis by MAP kinases.” In Faseb Journal, 14:A1372–A1372. FEDERATION AMER SOC EXP BIOL, 2000.Link to Item
-
Abner, A., S. Schnitt, J. Connolly, A. Recht, B. Bornstein, A. Nixon, S. Hetelekidis, B. Silver, and J. R. Harris. “2039 The relationship between the presence and extent of lobular carcinoma in situ (LCIS) and the risk of local recurrence (LR) in patients with infiltrating cancer of the breast treated with conservative surgery (CS) and radiation therapy (RT).” In International Journal of Radiation Oncology*Biology*Physics, 39:260–260. Elsevier BV, 1997. https://doi.org/10.1016/s0360-3016(97)80808-5.Full Text
-
Nixon, A. B., M. C. Seeds, P. K. Smitherman, D. A. Bass, and R. L. Wykle. “Comparison of alkylacylglycerol (EAG) and diacylglycerol (AAG) as activators of map kinase(s) and cytosolic PLA(2) in human neutrophil priming.” In Faseb Journal, 10:L6–L6. FEDERATION AMER SOC EXP BIOL, 1996.Link to Item
-
OFlaherty, J. T., M. Kuroki, L. W. Daniel, R. L. Wykle, A. B. Nixon, and S. Sozzani. “The targeting of leukocytes by 5-oxo-eicosanoids.” In Frontiers in Bioactive Lipids, edited by J. Y. Vanderhoek, 149–55. PLENUM PRESS DIV PLENUM PUBLISHING CORP, 1996.Link to Item
-
NIXON, A. B., D. G. GREENE, and R. L. WYKLE. “COMPARISON OF ACCEPTOR AND DONOR SUBSTRATES IN THE COA-INDEPENDENT TRANSACYLASE (COA-IT) REACTION IN HUMAN NEUTROPHILS.” In Faseb Journal, 9:A1307–A1307. FEDERATION AMER SOC EXP BIOL, 1995.Link to Item
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.